Merck, Keytruda and patent

New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
New version of Merck's Keytruda faces possible patent battle, WSJ reports
Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Merck injected version of Keytruda faces possible patent challenge: Report
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent dispute, according to a report by The Wall Street Journal
Merck (MRK) Battling to Protect Key Cancer Drug as Patent Row Heats Up
Shares in pharmaceuticals giant Merck (MRK) weakened today on fears that a patent battle could jeopardize its plans to sell a new version of
Merck set for patent battle with Halozyme over injectable Keytruda: WSJ
Merck (MRK) stock trended lower as Halozyme (HALO) challenges the company over injectable Keytruda patents. Read more here.
New version of Merck's cancer drug faces possible patent battle: reports
Halozyme Therapeutics claims Merck's new Keytruda version infringes on patents, requiring a licensing agreement, reports WSJ.
Merck’s Keytruda subject of brewing patent dispute with Halozyme, WSJ says
Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in
BioSpace23h
Merck’s Injectable Keytruda Plans Create Legal Dispute With Halozyme: WSJ
The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...
Forbes6d
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto ...
Nasdaq20d
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
Halozyme Therapeutics HALO is scheduled to report fourth-quarter and full-year 2024 results on Feb. 18, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues ...
Yahoo Finance15d
Halozyme Therapeutics: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Halozyme Therapeutics Inc. (HALO) on Tuesday reported fourth-quarter profit of $137 million. The San Diego-based company said it had net income of $1.06 per ...